NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

全球抗肥胖藥市場:2021年∼2025年

Global Anti-obesity Drugs Market 2021-2025

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 995541
出版日期 內容資訊 英文 120 Pages
訂單完成後即時交付
價格
全球抗肥胖藥市場:2021年∼2025年 Global Anti-obesity Drugs Market 2021-2025
出版日期: 2021年03月05日內容資訊: 英文 120 Pages
簡介

全球抗肥胖藥的市場規模在2021年∼2025年間,預測將成長到4億5451萬美元,在預測期間中預計將以5%的年複合成長率增長。

市場成長的主要因素有有限數量的批准藥物,僅限病理性肥胖的肥胖手術。

這份報告提供全球抗肥胖藥市場整體分析,市場規模與預測,趨勢,涵括成長要素,課題,以及約25位供應商的供應商分析。

目錄

摘要整理

市場形勢

市場規模

  • 市場定義
  • 市場區隔分析
  • 年貨市場規模
  • 市場預測:從2020年∼2025年的預測

波特的五力分析

市場區隔:各類型

  • 市場區隔
  • 各類型比較
  • III級抗肥胖藥:市場規模與預測(2020年∼2025年)
  • II級抗肥胖藥:市場規模與預測(2020年∼2025年)
  • I級抗肥胖藥:市場規模與預測(2020年∼2025年)
  • 各類型的市場機會

市場區隔:各作用機制

  • 市場區隔
  • 中樞作用性抗肥胖藥
  • 末梢作用性抗肥胖藥
  • 其他抗肥胖藥

客戶形勢

各地區形勢

  • 各地區市場區隔
  • 各地區比較
  • 北美:市場規模與預測(2020年∼2025年)
  • 歐洲:市場規模與預測(2020年∼2025年)
  • 亞洲:市場規模與預測(2020年∼2025年)
  • 其他地區:市場規模與預測(2020年∼2025年)
  • 主要國家
  • 各地區的市場機會
  • 市場推動因素
  • 市場課題
  • 市場趨勢

業者情勢

  • 概要
  • 創造性破壞狀況

供應商分析

  • 交易廠商
  • 供應商的市場定位
  • Bausch Health Companies Inc.
  • Currax Pharmaceuticals LLC
  • F. Hoffmann-La Roche Ltd.
  • Gelesis Inc.
  • GlaxoSmithKline Plc
  • Novo Nordisk AS
  • RECORDATI S.p.A.
  • Teva Pharmaceutical Industries Ltd.
  • VIVUS Inc.

附錄

目錄
Product Code: IRTNTR70300

Technavio has been monitoring the anti-obesity drugs market and it is poised to grow by $ 454.51 mn during 2021-2025 decelerate at a CAGR of 5% during the forecast period. Our reports on anti-obesity drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the limited number of approved drugs and use of bariatric surgery limited for morbid obesity. In addition, limited number of approved drugs is anticipated to boost the growth of the market as well.

The anti-obesity drugs market analysis includes type segment and geographical landscapes.

Technavio's anti-obesity drugs market is segmented as below:

By Type

  • class III anti-obesity drugs
  • class II anti-obesity drugs
  • class I anti-obesity drugs

By Geographical Landscapes

  • North America
  • Europe
  • Asia
  • ROW

This study identifies the growing obese population as one of the prime reasons driving the anti-obesity drugs market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on anti-obesity drugs market covers the following areas:

  • Anti-obesity drugs market sizing
  • Anti-obesity drugs market forecast
  • Anti-obesity drugs market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading anti-obesity drugs market vendors that include Bausch Health Companies Inc., Currax Pharmaceuticals LLC, F. Hoffmann-La Roche Ltd., Gelesis Inc., GlaxoSmithKline Plc, Novo Nordisk AS, RECORDATI S.p.A., Rhythm Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., and VIVUS Inc.. Also, the anti-obesity drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Market characteristics
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2020
  • Market outlook: Forecast for 2020 - 2025

Five Forces Analysis

  • Five Forces Summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Type

  • Market segments
  • Comparison by Type
  • Class III anti-obesity drugs - Market size and forecast 2020-2025
  • Class II anti-obesity drugs - Market size and forecast 2020-2025
  • Class I anti-obesity drugs - Market size and forecast 2020-2025
  • Market opportunity by Type

Market segmentation by Mechanism of Action

  • Market segments
  • Centrally acting anti-obesity drugs
  • Peripherally acting anti-obesity drugs
  • Other anti-obesity drugs

Customer landscape

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2020-2025
  • Europe - Market size and forecast 2020-2025
  • Asia - Market size and forecast 2020-2025
  • ROW - Market size and forecast 2020-2025
  • Key leading countries
  • Market opportunity by geography
  • Market drivers
  • Market challenges
  • Market trends

Vendor Landscape

  • Overview
  • Landscape disruption

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • Bausch Health Companies Inc.
  • Currax Pharmaceuticals LLC
  • F. Hoffmann-La Roche Ltd.
  • Gelesis Inc.
  • GlaxoSmithKline Plc
  • Novo Nordisk AS
  • RECORDATI S.p.A.
  • Teva Pharmaceutical Industries Ltd.
  • VIVUS Inc.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibit

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2020 - 2025 ($ million)
  • 13: Global market: Year-over-year growth 2020 - 2025 (%)
  • 14: Five forces analysis 2020 & 2025
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2020
  • 21: Class III anti-obesity drugs - Market size and forecast 2020-2025 ($ million)
  • 22: Class III anti-obesity drugs - Year-over-year growth 2020-2025 (%)
  • 23: Class II anti-obesity drugs - Market size and forecast 2020-2025 ($ million)
  • 24: Class II anti-obesity drugs - Year-over-year growth 2020-2025 (%)
  • 25: Class I anti-obesity drugs - Market size and forecast 2020-2025 ($ million)
  • 26: Class I anti-obesity drugs - Year-over-year growth 2020-2025 (%)
  • 27: Customer landscape
  • 28: Impact of drivers and challenges
  • 29: Vendor landscape
  • 30: Landscape disruption
  • 31: Industry risks
  • 32: Vendors covered
  • 33: Market positioning of vendors
  • 34: Bausch Health Companies Inc. - Overview
  • 35: Bausch Health Companies Inc. - Business segments
  • 36: Bausch Health Companies Inc. - Key offerings
  • 37: Bausch Health Companies Inc. - Key customers
  • 38: Bausch Health Companies Inc. - Segment focus
  • 39: Currax Pharmaceuticals LLC - Overview
  • 40: Currax Pharmaceuticals LLC - Product and service
  • 41: Currax Pharmaceuticals LLC - Key offerings
  • 42: Currax Pharmaceuticals LLC - Key customers
  • 43: Currax Pharmaceuticals LLC - Segment focus
  • 44: F. Hoffmann-La Roche Ltd. - Overview
  • 45: F. Hoffmann-La Roche Ltd. - Business segments
  • 46: F. Hoffmann-La Roche Ltd. - Key offerings
  • 47: F. Hoffmann-La Roche Ltd. - Key customers
  • 48: F. Hoffmann-La Roche Ltd. - Segment focus
  • 49: Gelesis Inc. - Overview
  • 50: Gelesis Inc. - Product and service
  • 51: Gelesis Inc. - Key offerings
  • 52: Gelesis Inc. - Key customers
  • 53: Gelesis Inc. - Segment focus
  • 54: GlaxoSmithKline Plc - Overview
  • 55: GlaxoSmithKline Plc - Business segments
  • 56: GlaxoSmithKline Plc - Key offerings
  • 57: GlaxoSmithKline Plc - Key customers
  • 58: GlaxoSmithKline Plc - Segment focus
  • 59: Novo Nordisk AS - Overview
  • 60: Novo Nordisk AS - Business segments
  • 61: Novo Nordisk AS - Key offerings
  • 62: Novo Nordisk AS - Key customers
  • 63: Novo Nordisk AS - Segment focus
  • 64: RECORDATI S.p.A. - Overview
  • 65: RECORDATI S.p.A. - Business segments
  • 66: RECORDATI S.p.A. - Key offerings
  • 67: RECORDATI S.p.A. - Key customers
  • 68: RECORDATI S.p.A. - Segment focus
  • 69: Rhythm Pharmaceuticals, Inc. - Overview
  • 70: Rhythm Pharmaceuticals, Inc. - Business segments
  • 71: Rhythm Pharmaceuticals, Inc. - Key offerings
  • 72: Rhythm Pharmaceuticals, Inc. - Key customers
  • 73: Rhythm Pharmaceuticals, Inc. - Segment focus
  • 74: Teva Pharmaceutical Industries Ltd. - Overview
  • 75: Teva Pharmaceutical Industries Ltd. - Business segments
  • 76: Teva Pharmaceutical Industries Ltd. - Key offerings
  • 77: Teva Pharmaceutical Industries Ltd. - Key customers
  • 78: Teva Pharmaceutical Industries Ltd. - Segment focus
  • 79: VIVUS Inc. - Overview
  • 80: VIVUS Inc. - Business segments
  • 81: VIVUS Inc. - Key offerings
  • 82: VIVUS Inc. - Key customers
  • 83: VIVUS Inc. - Segment focus
  • 84: Currency conversion rates for US$
  • 85: Research Methodology
  • 86: Validation techniques employed for market sizing
  • 87: Information sources
  • 88: List of abbreviations